Trial · NCT03909152
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
NCT03909152, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2025-07-28
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone. Trials, record NCT03909152. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03909152
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
- NCT number
- NCT03909152
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer
- Interventions
- Onapristone ER, Onapristone ER + Anastrozole
- First posted
- 2019-04-09
- Last updated
- 2025-07-28
- Results first posted
- 2025-07-28
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate | within 36 weeks | as determined by RECIST 1.1 response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = Complete Response + Partial Response (CR + PR) |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Overall Response Rate | within 36 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | Participants with Overall Response Rate (Complete Response + Partial Response) | 0 | Participants | |
| Overall Response Rate | PR+ Low Grade Serous Ovarian Cancer | Participants with Overall Response Rate (Complete Response + Partial Response) | 0 | Participants | |
| Overall Response Rate | PR+ Endometrioid Endometrial Cancer | Participants with Overall Response Rate (Complete Response + Partial Response) | 0 | Participants | |
| Overall Response Rate | PR+ Granulosa Cell Ovarian Cancer | Participants with Overall Response Rate (Complete Response + Partial Response) | 0 | Participants | |
| Overall Response Rate | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | Participants with no Overall Response Rate (Complete Response + Partial Response) | 14 | Participants | |
| Overall Response Rate | PR+ Low Grade Serous Ovarian Cancer | Participants with no Overall Response Rate (Complete Response + Partial Response) | 5 | Participants | |
| Overall Response Rate | PR+ Endometrioid Endometrial Cancer | Participants with no Overall Response Rate (Complete Response + Partial Response) | 1 | Participants | |
| Overall Response Rate | PR+ Granulosa Cell Ovarian Cancer | Participants with no Overall Response Rate (Complete Response + Partial Response) | 14 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 14 | |
| Overall Study | STARTED | PR+ Low Grade Serous Ovarian Cancer | 5 | |
| Overall Study | STARTED | PR+ Endometrioid Endometrial Cancer | 1 | |
| Overall Study | STARTED | PR+ Granulosa Cell Ovarian Cancer | 14 | |
| Overall Study | COMPLETED | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 0 | |
| Overall Study | COMPLETED | PR+ Low Grade Serous Ovarian Cancer | 0 | |
| Overall Study | COMPLETED | PR+ Endometrioid Endometrial Cancer | 0 | |
| Overall Study | COMPLETED | PR+ Granulosa Cell Ovarian Cancer | 0 | |
| Overall Study | NOT COMPLETED | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 14 | |
| Overall Study | NOT COMPLETED | PR+ Low Grade Serous Ovarian Cancer | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events308
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 1 | 14 | |
| other | Abdominal distension | Gastrointestinal disorders | PR+ Low Grade Serous Ovarian Cancer | 0 | 5 | |
| other | Abdominal distension | Gastrointestinal disorders | PR+ Endometrioid Endometrial Cancer | 0 | 1 | |
| other | Abdominal distension | Gastrointestinal disorders | PR+ Granulosa Cell Ovarian Cancer | 0 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 4 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | PR+ Low Grade Serous Ovarian Cancer | 1 | 5 | |
| other | Abdominal pain | Gastrointestinal disorders | PR+ Endometrioid Endometrial Cancer | 0 | 1 | |
| other | Abdominal pain | Gastrointestinal disorders | PR+ Granulosa Cell Ovarian Cancer | 3 | 14 | |
| other | Alanine aminotransferase increased | Investigations | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 0 | 14 | |
| other | Alanine aminotransferase increased | Investigations | PR+ Low Grade Serous Ovarian Cancer | 0 | 5 |
1 to 10 of 308Source ClinicalTrials.gov
See all 308 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 0 | 14 |
| Total, all-cause mortality | PR+ Low Grade Serous Ovarian Cancer | 0 | 5 |
| Total, all-cause mortality | PR+ Endometrioid Endometrial Cancer | 0 | 1 |
| Total, all-cause mortality | PR+ Granulosa Cell Ovarian Cancer | 0 | 14 |
| Total, other adverse events | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 14 | 14 |
| Total, other adverse events | PR+ Low Grade Serous Ovarian Cancer | 5 | 5 |
| Total, other adverse events | PR+ Endometrioid Endometrial Cancer | 1 | 1 |
| Total, other adverse events | PR+ Granulosa Cell Ovarian Cancer | 14 | 14 |
| Total, serious adverse events | PR+ Granulosa Cell Tumor (This Arm is CLOSED) | 2 | 14 |
| Total, serious adverse events | PR+ Low Grade Serous Ovarian Cancer | 3 | 5 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03909152
GET https://conductscience.org/api/trials/v1/NCT03909152/events?page=2